Oral contraceptives and premenstrual symptoms: Comparison of a 21/7 and extended regimen

Department of Obstetrics and Gynecology, Scott & White Memorial Hospital, Texas A&M University System Health Science Center College of Medicine, Temple, TX 76508, USA.
American journal of obstetrics and gynecology (Impact Factor: 3.97). 12/2006; 195(5):1311-9. DOI: 10.1016/j.ajog.2006.05.012
Source: PubMed

ABSTRACT The purpose of this study was to assess the incidence and severity of premenstrual-type symptoms in patients converted from a 21/7 oral contraceptive (OC) regimen to an extended regimen.
This was a single center prospective analysis of the single item Scott and White (S&W) Mood Scale and the Penn State Daily Symptom Report (DSR17) during a 21/7-day followed by a 168-day extended regimen of an OC containing 3 mg of drosperinone and 30 microg of ethinyl estradiol (DRSP/EE).
Of the 114 patients who began the study, 111 completed the preextension 21/7 phase of the study. There were significant differences in severity in the DSR17 and the S&W mood scale among days of the cycle. (P < .0001) The highest values in both scales occurred during the 7-day hormone free interval (HFI) of the 21/7 cycles (P < .001). Of the 111 patients who completed the 21/7 phase of the study, 102 (92%) completed the 168-day extended regimen. During the extended phase of the study, subjects were divided into 2 groups: those with a 100% increase in symptoms from the first half to the second half of the last 21/7 cycle were labeled as high cyclic variability, whereas those with lesser or no cyclic change were labeled as low cyclic variability. There were 55 (54%) with increased cyclic variability in mood scores peaking during the 7-day HFI. Premenstrual-type symptoms measured by both the S&W mood scale and the DSR17 instrument decreased during the extended DRSP/EE OC regimen (P < .0001) compared with the preceding 21/7 cycle, with the greatest improvement detected in the sixth month of continuous OCs (P < .003). The patient group with greatest cyclic variability during the 21/7 regimen demonstrated the most improvement during the 168-day regimen (P < .0001). The single item S&W mood scale was significantly (P < .05) correlated to each of 17 elements of the DSR17 with Spearman R correlation coefficients of 0.25 to 0.57. The greatest correlation coefficient (Spearman's R = 0.66) is with the sum of all 17 items.
A 168-day extended regimen of DRSP/EE led to a decrease in premenstrual-type symptoms compared with the 21/7-day regimen.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Key contentDysmenorrhoea can be treated successfully with combined oral contraceptives.Combined oral contraceptives have been shown to reduce and regulate menstrual bleeding.Combined oral contraceptives can treat acne in women also desiring contraception.Severe premenstrual syndrome may respond to drospirenone-containing combined oral contraceptives.Use of combined oral contraceptives decreases the risk of endometrial and ovarian cancer. Learning objectivesTo explain the role of combined oral contraceptives in reducing the risk of cancer.To identify the uses of combined oral contraceptives in treating gynaecological problems such as dysmenorrhoea, abnormal uterine bleeding, premenstrual syndrome, acne, hirsutism and polycystic ovary syndrome. Ethical issuesCompared with preventing pregnancy, the risk/benefit profile of combined oral contraceptives for non-contraceptive indications may be different and women should be counseled according to their individual circumstance.
    The Obstetrician & Gynaecologist 10/2012; 14(4). DOI:10.1111/j.1744-4667.2012.00126.x
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective To assess whether continuous and extended regimens (CRs/ERs) of combined hormonal contraceptives (CHCs) improve symptoms related to withdrawal bleeding or the hormone-free interval and to compare the efficacy, safety, and cost of CRs/ERs to those of conventional 28-day regimens. Study design A literature search of the PubMed database was conducted for randomised clinical trials (RCTs) and observational studies published in any language between 2006 and 2013. Results Sixteen RCTs and 14 observational studies evaluated issues related to our objectives. CRs/ERs, whose efficacy and safety were comparable to those described for conventional regimens, were preferred due to their improvement of symptoms related to withdrawal bleeding or the hormone-free interval and the lower costs resulting from the reduced incidence of these symptoms. Conclusion The contraceptive efficacy and safety of CR/ER use of CHCs is at least equal to that of 28-days conventional regimens, and this use may have some cost savings. CRs/ERs are recommended for women willing to take a CHC for treatment of symptoms related to withdrawal bleeding or the hormone-free interval.
    The European Journal of Contraception and Reproductive Health Care 06/2014; 19(5). DOI:10.3109/13625187.2014.927423 · 1.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Extended use of the combined oral contraceptive pill (COC), defined as taking active pills for at least 28&emsp14;days, has been used in order to avoid bleeding at important times and to treat gynaecological conditions such as endometriosis. We examined the main issues involved in extended use of the COC and how it has evolved from being one of medicine's best-kept secrets to becoming more widely accepted by women and the medical community. Literature review, using Medline, Embase, Pubmed, CINHAL Plus, the Cochrane Database of Systematic Reviews and the Ovid database for all relevant clinical trials, systematic reviews, meta-analyses, literature reviews, scientific papers and individual opinions between 1950 and October 2013. Accumulating evidence supports various forms of extended pill use as suitable alternatives to the standard (21/7) regimen. In terms of user preference, much hinges on whether women wish to reduce the frequency or duration of scheduled bleeding on the combined pill. Available data on the safety of extended pill regimens do not give cause for concern, but longer term data should be collected. Information for women considering extended COC regimens should keep pace with research findings to ensure that women and clinicians are better informed about the choices available.
    Journal of Family Planning and Reproductive Health Care 04/2014; 40(2):133-41. DOI:10.1136/jfprhc-2013-100600 · 2.33 Impact Factor